LESL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LESL is not a good buy right now for a Beginner with a long-term focus and $50,000-$100,000 to invest. The stock has a mixed-to-weak setup: price action is below key resistance and momentum is negative, while the options market is bullish but likely reflecting speculation rather than a strong long-term trend. With no recent news catalyst, no strong insider buying, hedge funds actively selling, and no positive financial snapshot provided, the better call is to wait rather than buy immediately.
The technical trend is weak in the short term. MACD histogram is -0.086 and still expanding negatively, which points to fading momentum. RSI_6 at 44.864 is neutral, so the stock is not oversold enough to signal a clear rebound. The moving averages are technically constructive with SMA_5 > SMA_20 > SMA_200, but price action is still not strong enough to confirm a durable breakout. Current price at 8.81 is below the pivot of 9.867 and well under R1 at 11.746, with support near 7.988. The candlestick-pattern model also suggests downside bias, with a 60% chance of -1.11% next day, -0.71% next week, and -5.09% next month.
No news in the recent week means there is no fresh event-driven catalyst. Analyst Wolfe Research raised its target to $3 and kept Outperform, citing relatively strong Q2 results and cost-cutting benefits over the next 12 months. The bullish options skew also shows traders are leaning optimistic, and the moving average structure is still technically aligned in bullish order.
Hedge funds are selling aggressively, with selling increasing 986.28% over the last quarter. Mizuho lowered its target to $3.50 and kept a Neutral rating. There is no recent insider buying, no recent news catalyst, and no congress trading activity. The stock trend model points to negative near-term returns, and the price remains below the pivot level, showing weak current momentum.
No usable financial snapshot was provided because of an error, so I cannot verify revenue or earnings trends directly. Based on the analyst commentary, Leslie's latest quarter appears to have been relatively strong, and cost-cutting is helping results. The latest quarter season mentioned is Q2. Still, without the full financial data, the company's fundamental momentum cannot be confirmed well enough to support a strong buy decision.
Analyst sentiment is mixed but slightly improving on the bullish side. Wolfe Research raised its price target to $3 from $2 and kept Outperform after saying Q2 results were relatively strong and cost cuts should help over the next 12 months. Mizuho lowered its target to $3.50 from $4 and kept Neutral. Overall, Wall Street is split: there is an optimistic recovery/cost-control thesis, but the target prices are still far below the current market price, which limits the upside case.
